Anticancer Treatments and Cardiotoxicity: Mechanisms, Diagnostic and Therapeutic Interventions presents cutting edge research on the adverse cardiac effects of both radiotherapy and chemotherapy, brought together by leaders in the field. Cancer treatment-related cardiotoxicity is the leading cause of treatment-associated mortality in cancer survivors and is one of the most common post-treatment issues among survivors of adult cancer. Early detection of the patients prone to developing cardiotoxicity, taking in to account the type of treatment, history and other risk factors, is essential in the fight to decrease cardiotoxic mortality.
This illustrated reference describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment. In addition, new guidelines on imaging for the screening and monitoring of these patients are also presented. Anticancer Treatments and Cardiotoxicity is an essential reference for those involved in the research and treatment of cardiovascular toxicity.
1. Introduction - p. 183 2. References - p. 241 3. Section V: Detection of Cardiac Dysfunction and Predictors of Cardiotoxicity - p. 241 4. Chapter 23. Detection by Cardiac Imaging: LV Ejection Fraction, Diastolic Dysfunction, Tissue Doppler, and Speckle Tracking Echocardiography - p. 273 5. Chapter 24. The Role of Biomarkers: Troponins, BNP, MPO, and Other Biomarkers - p. 281 6. Chapter 25. Screening and Comprehensive Follow-Up Evaluation - p. 291 7. Chapter 26. Preoperative Assessment for Noncardiac Surgery - p. 301 8. Section VI: Cardiotoxicity in Childhood - p. 305 9. Chapter 27. Cardiotoxicity of Childhood Cancer Treatments - p. 309 10. Section VII: Management of Anticancer Drugs Related Cardiotoxicity - p. 321 11. Chapter 28. Nonpharmacologic Therapy - p. 329 12. Chapter 29. Beta-Blockers - p. 335 13. Chapter 30. Angiotensin-Converting Enzyme Inhibition - p. 339 14. Chapter 31. Diuretics - p. 343 15. Chapter 32. Antiarrhythmic Drugs - p. 345 16. Chapter 33. Anticoagulation in Cancer Patients - p. 349 17. Chapter 34. New Drugs: The Beneficial Effects of Ranolazine - p. 353 18. Chapter 35. Percutaneous Coronary Intervention and Cardiac Surgery in Cancer Patients - p. 357 19. Chapter 36. Focus on the Patient With Known Cardiac Disease - p. 363 20. Chapter 37. Multidisciplinary Approach to Cardiac Disease in Cancer Patients - p. 369 21. Section VIII: Future Research Priorities - p. 374 22. Chapter 38. Pharmacogenomics Screening - p. 379 23. Chapter 39. Cardiac Monitoring During Clinical Trials - p. 387 24. Chapter 40. Preventive Therapy - p. 401 25. Chapter 41. Cardiotoxicity: Future Research Directions - p. 409 26. Multiple Choice Questions - p. 413 27. Index - p. 429
Anticancer Treatments and Cardiotoxicity: Mechanisms, Diagnostic and Therapeutic Interventions presents cutting edge research on the adverse cardiac effects of both radiotherapy and chemotherapy, brought together by leaders in the field. Cancer treatment-related cardiotoxicity is the leading cause of treatment-associated mortality in cancer survivors and is one of the most common post-treatment issues among survivors of adult cancer. Early detection of the patients prone to developing cardiotoxicity, taking in to account the type of treatment, history and other risk factors, is essential in the fight to decrease cardiotoxic mortality.
This illustrated reference describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment. In addition, new guidelines on imaging for the screening and monitoring of these patients are also presented. Anticancer Treatments and Cardiotoxicity is an essential reference for those involved in the research and treatment of cardiovascular toxicity.
1. Introduction - p. 183 2. References - p. 241 3. Section V: Detection of Cardiac Dysfunction and Predictors of Cardiotoxicity - p. 241 4. Chapter 23. Detection by Cardiac Imaging: LV Ejection Fraction, Diastolic Dysfunction, Tissue Doppler, and Speckle Tracking Echocardiography - p. 273 5. Chapter 24. The Role of Biomarkers: Troponins, BNP, MPO, and Other Biomarkers - p. 281 6. Chapter 25. Screening and Comprehensive Follow-Up Evaluation - p. 291 7. Chapter 26. Preoperative Assessment for Noncardiac Surgery - p. 301 8. Section VI: Cardiotoxicity in Childhood - p. 305 9. Chapter 27. Cardiotoxicity of Childhood Cancer Treatments - p. 309 10. Section VII: Management of Anticancer Drugs Related Cardiotoxicity - p. 321 11. Chapter 28. Nonpharmacologic Therapy - p. 329 12. Chapter 29. Beta-Blockers - p. 335 13. Chapter 30. Angiotensin-Converting Enzyme Inhibition - p. 339 14. Chapter 31. Diuretics - p. 343 15. Chapter 32. Antiarrhythmic Drugs - p. 345 16. Chapter 33. Anticoagulation in Cancer Patients - p. 349 17. Chapter 34. New Drugs: The Beneficial Effects of Ranolazine - p. 353 18. Chapter 35. Percutaneous Coronary Intervention and Cardiac Surgery in Cancer Patients - p. 357 19. Chapter 36. Focus on the Patient With Known Cardiac Disease - p. 363 20. Chapter 37. Multidisciplinary Approach to Cardiac Disease in Cancer Patients - p. 369 21. Section VIII: Future Research Priorities - p. 374 22. Chapter 38. Pharmacogenomics Screening - p. 379 23. Chapter 39. Cardiac Monitoring During Clinical Trials - p. 387 24. Chapter 40. Preventive Therapy - p. 401 25. Chapter 41. Cardiotoxicity: Future Research Directions - p. 409 26. Multiple Choice Questions - p. 413 27. Index - p. 429
